MindMaze Therapeutics Reports 2026 Half-Year Results and Corporate Update

Expanded U.S. commercial capabilities and reach through the build-out of the Company’s commercial organization, continued development of its customer pipeline, and a channel partnership with Vibra Healthcare.

Compelling real-world evidence from a two-year, multi-site program with Vibra Healthcare demonstrated significantly improved patient outcomes with high-dose, high-intensity neurorehabilitation.

Advanced its European reimbursement strategy with first patient enrollment in SwissNeuroRehab and launch of the REACT-AVC study in France.

Expanded the clinical application of the platform through support for a University of Pittsburgh study pairing spinal cord stimulation with high-dose, high-intensity neurotherapy for stroke recovery.

Completed organizational simplification, including the disposal of non-neurology legacy operations, resulting in a focused organization and reduced cost base.

Received CHF 4.0 million under a CHF 8.0 million equity financing agreement, with the remaining investment scheduled for the second half of 2026.

Reported H1 2026 revenue of CHF 0.5 million and net loss of CHF 6.9 million.

Zach Henderson, Chief Executive Officer of MindMaze Therapeutics, commented: “We made important progress during the first part of this year in capitalizing on our strong foundations and building our commercial capabilities. We have a differentiated platform developed over many years, robust clinical evidence, and an expanding presence in the United States. With the organizational simplification now completed and commercial momentum building across a growing pipeline of opportunities, our focus is firmly on execution: accelerating commercial adoption, advancing strategic and pharmaceutical collaborations, and translating the strength of our platform into sustainable revenue growth.”